BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) Short Interest Update

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) saw a significant increase in short interest in August. As of August 14th, there was short interest totaling 111,892 shares, an increase of ∞ from the July 30th total of 0 shares. Approximately 0.4% of the shares of the stock are short sold. Based on an average trading volume of 360,667 shares, the short-interest ratio is currently 0.3 days.

BlossomHill Therapeutics Price Performance

Shares of BLSM stock traded down $1.18 during trading hours on Monday, hitting $18.38. 41,510 shares of the company’s stock were exchanged, compared to its average volume of 227,669. BlossomHill Therapeutics has a 12-month low of $15.25 and a 12-month high of $20.61.

Insider Buying and Selling at BlossomHill Therapeutics

In other news, Director Orbimed Advisors Llc purchased 625,000 shares of the business’s stock in a transaction on Monday, August 10th. The stock was purchased at an average cost of $16.00 per share, with a total value of $10,000,000.00. Following the acquisition, the director directly owned 2,714,279 shares in the company, valued at approximately $43,428,464. This trade represents a 29.91% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Vincent Paul Liptak purchased 2,200 shares of BlossomHill Therapeutics stock in a transaction dated Monday, August 10th. The shares were purchased at an average price of $16.00 per share, with a total value of $35,200.00. Following the completion of the transaction, the general counsel directly owned 111,412 shares in the company, valued at approximately $1,782,592. This represents a 2.01% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 1,573,900 shares of company stock worth $25,181,900 in the last ninety days.

Analysts Set New Price Targets

Separately, Wall Street Zen raised BlossomHill Therapeutics to a “hold” rating in a research note on Saturday, August 15th.

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.